Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...